Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MC18 is a fluorine-18 labeled radiopharmaceutical developed by the University Medical Center Groningen (UMCG) as a lead positron emission tomography (PET) tracer for imaging P-glycoprotein (P-gp) function. P-glycoprotein, encoded by the ABCB1 gene, is a key efflux transporter at the blood-brain barrier (BBB) that limits the entry of various therapeutic drugs into the central nervous system. MC18 is a structural derivative of the potent P-gp inhibitor tariquidar and was designed to act as a substrate for the transporter, enabling the non-invasive quantification of P-gp transport activity and expression in vivo. While it has been primarily utilized in preclinical research and early-phase clinical evaluation, it serves as a critical tool for investigating the role of P-gp dysfunction in neurodegenerative diseases such as Alzheimer's and Parkinson's disease, as well as in the mechanisms of drug resistance in epilepsy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MC18.